Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedSep 15, 2026
DataAggregated Company Financials
Companies1376
  • 7D-2.4%
  • 3M10.2%
  • 1Y24.2%
  • YTD8.6%

Over the last 7 days, the Healthcare industry has dropped 2.4%, driven by a pullback from Amgen of 13%. In the past year, the industry has gained 24%. Earnings are forecast to grow by 21% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 15 Sep 2026US$7.0tUS$3.4tUS$118.8b25.2x58.8x2.1x
Thu, 13 Aug 2026US$7.1tUS$3.4tUS$116.1b26x61.3x2.1x
Sat, 11 Jul 2026US$7.0tUS$3.3tUS$122.0b25x57.2x2.1x
Mon, 08 Jun 2026US$6.4tUS$3.3tUS$122.5b23.6x52.6x1.9x
Wed, 06 May 2026US$6.2tUS$3.3tUS$117.5b23.8x52.6x1.9x
Fri, 03 Apr 2026US$6.2tUS$3.3tUS$128.3b22.2x48.5x1.9x
Sun, 01 Mar 2026US$6.7tUS$3.3tUS$127.5b25.5x52.2x2x
Tue, 27 Jan 2026US$6.6tUS$3.2tUS$130.6b29.1x50.6x2.1x
Thu, 25 Dec 2025US$6.6tUS$3.2tUS$135.2b26.4x48.5x2.1x
Sat, 22 Nov 2025US$6.2tUS$3.2tUS$133.4b25.8x46.7x2x
Mon, 20 Oct 2025US$6.0tUS$3.1tUS$140.4b24.8x42.5x1.9x
Wed, 17 Sep 2025US$5.7tUS$3.1tUS$137.5b23.8x41.2x1.8x
Fri, 15 Aug 2025US$5.6tUS$3.1tUS$136.9b23.4x40.5x1.8x
Sun, 13 Jul 2025US$5.5tUS$3.0tUS$127.9b24x43.3x1.8x
Tue, 10 Jun 2025US$5.5tUS$3.0tUS$127.2b23.8x43.2x1.8x
Thu, 08 May 2025US$5.4tUS$3.0tUS$127.1b25x42.7x1.8x
Sat, 05 Apr 2025US$5.5tUS$2.6tUS$82.1b24.7x67x2.1x
Mon, 03 Mar 2025US$5.9tUS$2.6tUS$79.3b27.5x74x2.2x
Wed, 29 Jan 2025US$6.2tUS$2.9tUS$85.5b27.9x72x2.1x
Fri, 27 Dec 2024US$5.9tUS$2.9tUS$78.3b27.6x74.8x2x
Sun, 24 Nov 2024US$6.0tUS$2.9tUS$77.3b28.2x78.1x2.1x
Tue, 22 Oct 2024US$6.2tUS$2.8tUS$58.7b32.1x106.4x2.2x
Thu, 19 Sep 2024US$6.3tUS$2.8tUS$60.2b31.1x104.5x2.2x
Sat, 17 Aug 2024US$6.1tUS$2.8tUS$56.1b32.8x109.5x2.2x
Mon, 15 Jul 2024US$6.3tUS$2.8tUS$62.2b31.2x101.7x2.2x
Wed, 12 Jun 2024US$6.2tUS$2.8tUS$63.6b30.2x97.9x2.2x
Fri, 10 May 2024US$6.1tUS$2.8tUS$62.9b30.6x96.7x2.2x
Sun, 07 Apr 2024US$6.2tUS$2.8tUS$84.1b32.4x73.2x2.2x
Tue, 05 Mar 2024US$6.3tUS$2.8tUS$85.0b31x74x2.3x
Thu, 01 Feb 2024US$6.4tUS$2.8tUS$80.6b31.6x79.2x2.3x
Sat, 30 Dec 2023US$6.2tUS$2.8tUS$91.5b32.6x68.2x2.2x
Mon, 27 Nov 2023US$5.9tUS$2.8tUS$91.4b28.6x64.4x2.1x
Wed, 25 Oct 2023US$5.7tUS$2.8tUS$99.6b24.8x57.3x2x
Fri, 22 Sep 2023US$5.9tUS$2.8tUS$98.6b27.4x60.1x2.1x
Price to Earnings Ratio

60.1x


Total Market Cap: US$5.9tTotal Earnings: US$98.6bTotal Revenue: US$2.8tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 65.5x202420252026
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 58.8x which is lower than its 3-year average PE of 65.5x.
  • The industry is trading close to its 3-year average PS ratio of 2.1x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 6.4% per year over the last three years.
  • Revenues for these companies have grown 6.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market-1.54%
Healthcare-2.44%
Healthcare Services-0.37%
Life Sciences-0.96%
Healthtech-2.19%
Pharma-2.34%
Medical Equipment-3.58%
Biotech-3.87%
Industry PE
  • Investors are most optimistic about the Life Sciences industry, which is trading close to its 3-year average PE ratio of 55.3x.
    • Analysts are expecting annual earnings growth of 18.6%, which is higher than its past year's earnings growth of 9.6% per year.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 29% over the next 5 years.
  • However this is lower than its past earnings growth rate of 65% per year.
  • In contrast, the Medical Equipment industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$261.772.1%
+US$9.4b		20.3%PE73.8x
HCA HCA HealthcareUS$425.495.1%
+US$4.4b		5.5%PE13.5x
ROIV Roivant SciencesUS$41.0217.4%
+US$4.4b		194.1%PS3933.8x
ISRG Intuitive SurgicalUS$377.943.1%
+US$4.0b		-12.9%PE42.5x
ELV Elevance HealthUS$424.244.1%
+US$3.6b		38.2%PE18.5x

Latest News

JNJ
US$266.32
Johnson & Johnson
7D
-3.2%
1Y
50.1%
ISRG
US$377.94
Intuitive Surgical
7D
3.1%
1Y
-12.9%
SYK
US$281.87
Stryker
7D
-7.0%
1Y
-25.3%
Seeking Alpha • 22h

Stryker: Operational Issues Have Created An Opportunity

Summary Stryker's share price has declined significantly in recent months on the back of operational issues, valuation concerns, and weaker orthopedic procedure volume growth. Despite headwinds, Stryker's growth is still solid and should rebound once the Vascular manufacturing issue is resolved. Further margin expansion is also an underappreciated part of the Stryker story. The stock pullback appears overdone, with strong returns likely as growth rebounds and margins continue to trend higher. Read the full article on Seeking Alpha
NTRA
US$341.79
Natera
7D
4.1%
1Y
98.5%
ABBV
US$261.77
AbbVie
7D
2.1%
1Y
20.3%
VRTX
US$519.51
Vertex Pharmaceuticals
7D
-4.9%
1Y
32.1%
ROIV
US$41.02
Roivant Sciences
7D
17.4%
1Y
194.1%
Seeking Alpha • Sep 13

Roivant Sciences: Diverse Exposure To Biotech Niches Through Vants

Summary LISRAYA’s recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV’s pulmonary asset with mosliciguat is also promising. This candidate may be helpful for vascular resistance and walking distance improvements. I believe mosliciguat could over time become a valuable pulmonary franchise, but we still need to see how its subsequent Phase 3 plays out. Overall, I think ROIV’s valuation still seems compelling if we assume management ultimately delivers on their long-term peak sales targets. Read the full article on Seeking Alpha
LLY
US$1,138.28
Eli Lilly
7D
-1.0%
1Y
52.1%
MRK
US$144.85
Merck
7D
-3.6%
1Y
78.8%
TEVA
US$38.72
Teva Pharmaceutical Industries
7D
6.5%
1Y
105.0%
Narrative Update • Sep 09

TEVA: Celiac And Vitiligo Data Are Expected To Drive Neuroscience Pivot

Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries to $41.91 from $40.90, citing stronger assumed revenue growth, a slightly higher future P/E multiple, and recent Street research that highlights commercial execution and a maturing pipeline in areas such as celiac disease and Tourette's syndrome. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries focuses on how the company is executing on its growth plans and how that might support current valuation levels.
UNH
US$383.55
UnitedHealth Group
7D
-3.4%
1Y
10.3%
HCA
US$425.49
HCA Healthcare
7D
5.1%
1Y
5.5%
AMGN
US$381.50
Amgen
7D
-12.7%
1Y
39.0%
CI
US$290.05
Cigna Group
7D
2.7%
1Y
-2.4%
ABT
US$103.09
Abbott Laboratories
7D
-4.8%
1Y
-21.5%
ELV
US$424.24
Elevance Health
7D
4.1%
1Y
38.2%